Forskning
Udskriv Udskriv
Switch language
Region Hovedstaden - en del af Københavns Universitetshospital
Udgivet

Meropenem to Children With Febrile Neutropenia Induces Monoresistant Pseudomonas aeruginosa

Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  1. Abdominal Complications During Treatment for Pediatric Acute Myeloid Leukemia

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  2. Can Machine Learning Models Predict Asparaginase-associated Pancreatitis in Childhood Acute Lymphoblastic Leukemia

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  3. Improved Survival of Children, Adolescents, and Young Adults With Head and Neck Soft Tissue Sarcomas in Denmark

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  4. Hearing Status in Survivors of Childhood Acute Myeloid Leukemia Treated With Chemotherapy Only: A NOPHO-AML Study

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  1. Changes in body mass index during treatment of childhood acute lymphoblastic leukemia with the Nordic ALL2008 protocol

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  2. Unexplained fever in children-Benefits and challenges of FDG-PET/CT

    Publikation: Bidrag til tidsskriftReviewForskningpeer review

  3. Vancomycin-resistant Enterococcus faecium: should we screen on admission?

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

Vis graf over relationer

Antimicrobial resistance in Pseudomonas aeruginosa is a threat to children with cancer. We explored the association between P. aeruginosa resistance and previous antibiotic exposure. All children with cancer and P. aeruginosa bacteremia in 2007 to 2016 in Denmark, a country with an overall resistance rate of ∼3%, were included. Twenty percent (10/49) of isolates from children previously exposed to meropenem were meropenem nonsusceptible. The only significant risk factor of meropenem nonsusceptibility was previous meropenem therapy (P=0.03). On the basis of these results, we suggest that meropenem should be reserved as a last resort for children with febrile neutropenia in countries with low antimicrobial resistance.

OriginalsprogEngelsk
TidsskriftJournal of Pediatric Hematology/Oncology
Vol/bind42
Udgave nummer8
Sider (fra-til)e783-e787
ISSN1077-4114
DOI
StatusUdgivet - nov. 2020

ID: 62063794